

# MONTHLY CROSSROAD

newsletter of  
heliosDX

## Better Laboratory Services is our Passion!

Written by Yann Gerville-Reache, COO

Are you ready to help millions of Americans that go undetected for diabetic and chronic kidney disease? Our newest test is here! **AutoUA®** is a top-notch, patented, quantitative urinalysis reagent system that provides 15 analytes of which 13 are 510K FDA cleared, and it results over 25 reportables. AutoUA® was developed with a passion around the early detection and prevention of chronic and diabetic kidney disease, and it's also designed to detect urinary tract infection, early stages of kidney failure, ketosis, diabetes, liver conditions, hormone levels and more. You can throw away the antiquated dipstick test and start truly helping the millions of americans that go undetected. For a full list, please reach out to us at the phone number below and find out more at [heliosdx.com/library](https://heliosdx.com/library). (AutoUA® is provided in partnership with Sciteck Diagnostics.)

Also, don't forget to get a test sample of our One-Touch Toxicology blood droplet kit. The panel, requisitions and related references can be found on our document library.

Thank you for being interested and keeping up to date on heliosDX. Check out more on our website and social media links found below.

### URINE, You're OUT!

Tired of managing cups of pee? Our **NEW Blood Droplet Test** is Here!

The NEW heliosDX Blood Droplet Test is designed to replace your old urine toxicology test. Samples are easy to collect, and no restroom visits or prep areas are required. The test offers over 60 analytes quantitated covering 22 classes, and can also measure 6 hormones.



## On the Calendar

July

New AutoUA reagent system testing release for early detection of kidney disease and more

New One-Touch Blood Toxicology Testing Service Rollout

National Minority Mental Health Awareness

Hepatitis Awareness





## LABORATORY EVOLUTION

heliosDX while our technical assessments for Palmetto GBA®'s MoIDX program, have been submitted and our PCR program hangs in the balance we surge forward. Our technical assessments are being reviewed, and we are anxiously anticipating their approval. We still intend on bringing additional PCR panels in-house. We currently offer a variety of PCR panels through our lab partners and will continue to do so for our customer base. In the meantime, we continue to innovate and find new opportunities to bring additional services to the patient. We've added the Blood Toxicology Panel, AutoUA® and UTI Screen. For the future, we're looking into other differentiating panels that complement the services and business.



## FAITH WILL PROSPER

heliosDX knows what it means to be challenged in this increasingly regulated market with the payers and the competition. We appreciate all of our customers' support and continued faith in our laboratory for providing fast, accurate, and reliable testing services. We're adding new customers and new testing to be able to provide the maximum potential back to the healthcare community and the patients that need the best care and healing. Our persistence and integrity has always paid off in the past and we will maintain those attributes as part of our core existence. Even in circumstances when it is unfavorable to us, we strive to provide the much needed services.



## REACHING NEW HEIGHTS

heliosDX, through its parent company RushNet, Inc. patiently awaits approvals from the SEC and FINRA to move forward on its plan to split out and become a separately traded public entity. With this milestone the company is set to proceed with acquiring another laboratory. The future developments we anticipate will serve us to grow our business, expand patient care, improve laboratory systems for user friendly experiences and streamlined processes. We look forward to sharing this achievement as soon as it becomes effective.

**"WE ARE ALWAYS FOCUSED ON UPHOLDING PATIENT CARE. FROM THE SYSTEMS WE USE TO THE SERVICES WE PROVIDE, WE ARE ALWAYS ASSESSING WHETHER THIS ADDS VALUE TO PATIENTS." ~ ASHLEY SWEAT, CEO**